



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Jia Yin,
✉ jia_yin@meei.harvard.edu
Kunpeng Pang,
✉ k.pang@sdu.edu.cn

SPECIALTY SECTION
This article was submitted to
Experimental Pharmacology and Drug
Discovery, a section of the journal
Frontiers in Pharmacology

RECEIVED 08 February 2023
ACCEPTED 09 February 2023
PUBLISHED 21 February 2023

CITATION
Zhu S, Shan H, Li J, Pan L, Wang S, Zhu J,
Guo H, Mi F, Wu X, Yin J and Pang K
(2023), Corrigendum: Therapeutic
potential of topical administration of
acriflavine against hypoxia-inducible
factors for corneal fibrosis.
Front. Pharmacol. 14:1161682.
doi: 10.3389/fphar.2023.1161682

COPYRIGHT
© 2023 Zhu, Shan, Li, Pan, Wang, Zhu,
Guo, Mi, Wu, Yin and Pang. This is an
open-access article distributed under the
terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Therapeutic potential of topical administration of acriflavine against hypoxia-inducible factors for corneal fibrosis

Shuyan Zhu¹, Huimin Shan², Jianqiao Li², Lijie Pan²,
Shudan Wang³, Jing Zhu², Hui Guo², Fenghua Mi², Xinyi Wu²,
Jia Yin^{3*} and Kunpeng Pang^{2*}

¹Xi'an People's Hospital (Xi'an Fourth Hospital), Shanxi Eye Hospital, Xi'an, China, ²Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, Shandong, China, ³Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA, United States

KEYWORDS

HIF, corneal fibrosis, corneal hypoxia, TGF- β 1, extracellular matrix

A Corrigendum on Therapeutic potential of topical administration of acriflavine against hypoxia-inducible factors for corneal fibrosis

by Zhu S, Shan H, Li J, Pan L, Wang S, Zhu J, Guo H, Mi F, Wu X and Pang K (2022). *Front. Pharmacol.* 13:996635. doi: 10.3389/fphar.2022.996635

In the published article, there was an error in the **Author** list, and author “Jia Yin” was erroneously excluded. The corrected **Author** list appears below.

“Shuyan Zhu¹, Huimin Shan², Jianqiao Li², Lijie Pan², Shudan Wang³, Jing Zhu², Hui Guo², Fenghua Mi², Xinyi Wu², Jia Yin^{3*}, Kunpeng Pang^{2*}.”

In the published article, Jia Yin's information was not included in the correspondence information. The corrected **Correspondence** information is “Jia Yin, jia_yin@meei.harvard.edu; Kunpeng Pang, k.pang@sdu.edu.cn.”

In the published article, the **Author Contributions** statement did not mention Jia Yin's contributions. The correct statement is “JY and KP contributed to conception and design of the study. KP supervised the study. SZ, HS, SW, and KP conducted experiments and acquired data; HS and KP wrote the manuscript; LP analyzed data; FM assisted in conducting the experiments; JZ and HG assisted in analyzing data; JL and XW provided the reagents; KP designed research studies and revised the manuscript.”

In the published article, the **Acknowledgements** statement was displayed as “We thank Dr. Jia Yin as an advisor for the hypoxia study.” The correct statement is “None.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.